Advanced Solutions
for Advanced Pathology
p21
WAF1
(DCS-60.2)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
44358 p21 RTU M (DCS-60.2)
7 ml Ready To Use
44736 p21 0,1 M (DCS-60.2)
100 µl liquid Concentrated
44737 p21 1 M (DCS-60.2)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Colon
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
2a
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
Product Description
p21 is a nuclear 21 kD protein, a product of the WAF1/CIP1 gene. It is a cyclin-dependent kinase inhibitor 1A (p21, Cip1), also known as CDKN1A,
which in humans is encoded by the CDKN1A gene located on chromosome (6p21.2). It is a constituent of a large complex of nuclear proteins,
including cyclins, cyclin dependent kinases, and PCNA. Cell cycle progression is regulated by cyclins and their cognate Cdks. p21 inhibits the
activity of each member of the cyclin/Cdk family. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly
controlled by the tumor suppressor protein p53. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression
has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).
Reference
1. DiGiuseppe JA, et al. Am J Pathol. 1995; 147:884-8.
2. Yoshitito Gomyo, et al. Cancer. 1997; 79:2067-2072.
3. Ikeguchi M, et al. Dig Dis Sci. 1998; 43:964-70.
4. Marone M, et al. Leuk Lymphoma. 2003; 43(1):51-7.
5. Kwon MS, et al. Pathol Res Pract. 2006; 202(12):849-56.
6. Elettra Merola, et al. J Cell Physi. 2006; 207:512-519.
7. Yoo J, et al. J Korean Med Sci. 2007 Apr; 22:318-25.
8. Tamura M, et al. Ann Thorac Cardiovasc Surg. 2007 Feb; 13(1):9-14.
187
